Rodrigo Cartin-Ceba1, Rolf D Hubmayr2, Rui Qin3, Steve Peters2, Rogier M Determann4, Marcus J Schultz4, Ognjen Gajic2. 1. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN. Electronic address: cartinceba.rodrigo@mayo.edu. 2. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN. 3. Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN. 4. Laboratory of Experimental Intensive Care and Anesthesiology and Department of Intensive Care, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Abstract
PURPOSE: To evaluate the predictive value of 6 different biomarkers in the development of multiple-organ failure (MOF) and mortality in a contemporary prospective cohort of acute respiratory distress syndrome (ARDS). METHODS: Patients with ARDS admitted to a tertiary referral center during an 8-month period were included. Plasma sample collection of 6 different biomarkers on days 1, 3, and 5 after ARDS onset was performed (von Willebrand factor, thrombin-antithrombin III complex, plasminogen activator inhibitor 1, interleukin 8, receptor for advanced glycation end-products, and club cell secretory protein). Main outcomes included hospital mortality and development of MOF. Logistic regression models for MOF and mortality prediction were created including biomarkers levels and clinical predictors. RESULTS: One hundred patients were included in the study. Do-not-resuscitate status and McCabe score were independently associated with increased mortality. None of the 6 biomarkers measured at the time of ARDS diagnosis predicted hospital mortality. After adjustment for important clinical characteristics, elevated day-1 interleukin 8 levels were associated with the development of MOF. CONCLUSIONS: Addition of biomarkers did not improve mortality prediction in this cohort of ARDS. Association between elevated interleukin 8 levels and progression of organ failures suggests an important role of exaggerated inflammatory response in the development of MOF.
PURPOSE: To evaluate the predictive value of 6 different biomarkers in the development of multiple-organ failure (MOF) and mortality in a contemporary prospective cohort of acute respiratory distress syndrome (ARDS). METHODS:Patients with ARDS admitted to a tertiary referral center during an 8-month period were included. Plasma sample collection of 6 different biomarkers on days 1, 3, and 5 after ARDS onset was performed (von Willebrand factor, thrombin-antithrombin III complex, plasminogen activator inhibitor 1, interleukin 8, receptor for advanced glycation end-products, and club cell secretory protein). Main outcomes included hospital mortality and development of MOF. Logistic regression models for MOF and mortality prediction were created including biomarkers levels and clinical predictors. RESULTS: One hundred patients were included in the study. Do-not-resuscitate status and McCabe score were independently associated with increased mortality. None of the 6 biomarkers measured at the time of ARDS diagnosis predicted hospital mortality. After adjustment for important clinical characteristics, elevated day-1 interleukin 8 levels were associated with the development of MOF. CONCLUSIONS: Addition of biomarkers did not improve mortality prediction in this cohort of ARDS. Association between elevated interleukin 8 levels and progression of organ failures suggests an important role of exaggerated inflammatory response in the development of MOF.
Authors: Heather Lynn; Xiaoguang Sun; Nancy Casanova; Manuel Gonzales-Garay; Christian Bime; Joe G N Garcia Journal: Antioxid Redox Signal Date: 2019-06-18 Impact factor: 8.401
Authors: Matthieu Jabaudon; Raiko Blondonnet; Bruno Pereira; Rodrigo Cartin-Ceba; Christoph Lichtenstern; Tommaso Mauri; Rogier M Determann; Tomas Drabek; Rolf D Hubmayr; Ognjen Gajic; Florian Uhle; Andrea Coppadoro; Antonio Pesenti; Marcus J Schultz; Marco V Ranieri; Helena Brodska; Ségolène Mrozek; Vincent Sapin; Michael A Matthay; Jean-Michel Constantin; Carolyn S Calfee Journal: Intensive Care Med Date: 2018-07-26 Impact factor: 17.440